Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024

Vivani Medical, Inc.

2024-Q2 EPS reported -$0.21

Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.
Net loss $5.3M vs $6.5M YoY; R&D expense $3.5M (-9% YoY), G&A $2.2M (-31% YoY).
FDA cleared IND for NPM-119 (six-month GLP-1 implant for type 2 diabetes) in June 2024.
First-in-human LIBERATE-1 study for NPM-115 (obesity implant) expected to start Q4 2024 in Australia, data in 2025.
Veterinary GLP-1 implant data published in BMC Veterinary Research; 40% of domestic cats overweight.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.